In his five years at Fred Hutch, Dr. Lynch has made landmark impacts, including successful merging previously separate research and clinical care organizations and strengthening the independent cancer center’s relationship with Seattle-based UW Medicine. He has overseen significant growth, with patient volumes increasing over 30% under his leadership, as well as expanded clinical trial locations. In 2022, Dr. Lynch helped secure two significant philanthropic gifts, totaling nearly $800 million, to expand precision oncology efforts. This past year, he led a nimble response to an opportunity that enabled Fred Hutch to add 300,000 square feet of research and lab space adjacent to its main campus. Fred Hutch has been home to three Nobel laureates and is the birthplace of bone marrow transplantation, and Dr. Lynch has built upon that legacy by recruiting strong clinical and research experts to Fred Hutch. He has strengthened the organization’s commitment to DEI, evidenced by a significant increase in executive team diversity and a doubling of underrepresented hires to 41% last year. Under Dr. Lynch’s leadership, Fred Hutch will mark its 50th anniversary in 2025 and has embarked on a $3 billion comprehensive campaign to support both clinical care and research.
